Hepatitis Monthly

Published by: Kowsar

Repression of the Internal Ribosome Entry Site-dependent Translation of Hepatitis C Virus by an Engineered PUF Protein

Seyed Jalal Kiani 1 , Tahereh Taheri 2 , Ahmad Nejati 1 , Monireh Maleki 3 , Sima Rafati 2 , Kayhan Azadmanesh 4 , Seyed Moayed Alavian 5 , Talat Mokhtari Azad 1 and Katayoun Samimi-Rad 1 , *
Authors Information
1 Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran
3 Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4 Virology Department, Pasteur Institute of Iran, Tehran, Iran
5 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatollah University of Medical Sciences, Tehran, Iran
Article information
  • Hepatitis Monthly: February 2017, 17 (2); e45022
  • Published Online: January 21, 2017
  • Article Type: Research Article
  • Received: December 24, 2016
  • Revised: January 3, 2017
  • Accepted: January 6, 2017
  • DOI: 10.5812/hepatmon.45022

To Cite: Kiani S J, Taheri T, Nejati A, Maleki M, Rafati S, et al. Repression of the Internal Ribosome Entry Site-dependent Translation of Hepatitis C Virus by an Engineered PUF Protein, Hepat Mon. 2017 ;17(2):e45022. doi: 10.5812/hepatmon.45022.

Abstract
Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4): 1333-42[DOI][PubMed]
  • 2. Roingeard P. Is hepatitis C virus eradication a realistic objective in the absence of a prophylactic vaccine? Liver Int. 2016; 36(7): 1076[DOI][PubMed]
  • 3. Cox AL. MEDICINE. Global control of hepatitis C virus. Science. 2015; 349(6250): 790-1[DOI][PubMed]
  • 4. AASLD-IDSA. . Recommendations for testing, managing, and treating hepatitis C.
  • 5. Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 2014; 105: 64-71[DOI][PubMed]
  • 6. Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology. 2016; 151(1): 70-86[DOI][PubMed]
  • 7. Tang H, Grise H. Cellular and molecular biology of HCV infection and hepatitis. Clin Sci (Lond). 2009; 117(2): 49-65[DOI][PubMed]
  • 8. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication. J Virol. 2001; 75(24): 12047-57[DOI][PubMed]
  • 9. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virus. J Gastroenterol. 2007; 42(6): 411-23[DOI][PubMed]
  • 10. Reynolds JE, Kaminski A, Kettinen HJ, Grace K, Clarke BE, Carroll AR, et al. Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J. 1995; 14(23): 6010-20[PubMed]
  • 11. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, et al. RNAi as a new therapeutic strategy against HCV. Biotechnol Adv. 2010; 28(1): 27-34[DOI][PubMed]
  • 12. Shum KT, Zhou J, Rossi JJ. Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel). 2013; 6(12): 1507-42[DOI][PubMed]
  • 13. Levesque MV, Levesque D, Briere FP, Perreault JP. Investigating a new generation of ribozymes in order to target HCV. PLoS One. 2010; 5(3): 9627[DOI][PubMed]
  • 14. Cooke A, Prigge A, Opperman L, Wickens M. Targeted translational regulation using the PUF protein family scaffold. Proc Natl Acad Sci U S A. 2011; 108(38): 15870-5[DOI][PubMed]
  • 15. Ozawa T, Natori Y, Sato M, Umezawa Y. Imaging dynamics of endogenous mitochondrial RNA in single living cells. Nature Methods. 2007; 4(5): 413-9[DOI]
  • 16. Tilsner J, Linnik O, Christensen NM, Bell K, Roberts IM, Lacomme C, et al. Live-cell imaging of viral RNA genomes using a Pumilio-based reporter. Plant J. 2009; 57(4): 758-70[DOI][PubMed]
  • 17. Wang Y, Cheong CG, Hall TM, Wang Z. Engineering splicing factors with designed specificities. Nat Methods. 2009; 6(11): 825-30[DOI][PubMed]
  • 18. Huang JY, Su WC, Jeng KS, Chang TH, Lai MM. Attenuation of 40S ribosomal subunit abundance differentially affects host and HCV translation and suppresses HCV replication. PLoS Pathog. 2012; 8(6): 1002766[DOI][PubMed]
  • 19. Kieft JS, Zhou K, Jubin R, Doudna JA. Mechanism of ribosome recruitment by hepatitis C IRES RNA. RNA. 2001; 7(2): 194-206[PubMed]
  • 20. Chevalier C, Saulnier A, Benureau Y, Flechet D, Delgrange D, Colbere-Garapin F, et al. Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs. Mol Ther. 2007; 15(8): 1452-62[DOI][PubMed]
  • 21. Korf M, Jarczak D, Beger C, Manns MP, Kruger M. Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol. 2005; 43(2): 225-34[DOI][PubMed]
  • 22. Kikuchi K, Umehara T, Fukuda K, Hwang J, Kuno A, Hasegawa T, et al. RNA aptamers targeted to domain II of hepatitis C virus IRES that bind to its apical loop region. J Biochem. 2003; 133(3): 263-70[PubMed]
  • 23. Wickens M, Bernstein DS, Kimble J, Parker R. A PUF family portrait: 3′UTR regulation as a way of life. Trends Genet. 2002; 18(3): 150-7[DOI]
  • 24. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1): 15-20[DOI][PubMed]
  • 25. Filipovska A, Razif MF, Nygard KK, Rackham O. A universal code for RNA recognition by PUF proteins. Nat Chem Biol. 2011; 7(7): 425-7[DOI][PubMed]
  • 26. Cheong CG, Hall TM. Engineering RNA sequence specificity of Pumilio repeats. Proc Natl Acad Sci U S A. 2006; 103(37): 13635-9[DOI][PubMed]
  • 27. Dong S, Wang Y, Cassidy-Amstutz C, Lu G, Bigler R, Jezyk MR, et al. Specific and modular binding code for cytosine recognition in Pumilio/FBF (PUF) RNA-binding domains. J Biol Chem. 2011; 286(30): 26732-42[DOI][PubMed]
  • 28. Choudhury R, Tsai YS, Dominguez D, Wang Y, Wang Z. Engineering RNA endonucleases with customized sequence specificities. Nat Commun. 2012; 3: 1147[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader